Mescaline (drug)

Mescaline (drug)
Name	Mescaline
Routes of administration	Oral
Class	Psychedelic
Cas number	54-04-6
Legal us	Schedule I

Mescaline (drug) Mescaline is a naturally occurring psychedelic alkaloid historically used in Indigenous Peyote, San Pedro cactus, and Peruvian torch sacramental contexts and later studied by chemists and psychiatrists. It gained attention through interactions with figures associated with Beat Generation, Counterculture of the 1960s, and researchers at institutions such as Harvard University and Johns Hopkins University. Its cultural, scientific, and legal trajectories intersect with events like the War on Drugs and regulatory actions by agencies such as the Drug Enforcement Administration.

History

Mescaline was first isolated and synthesized amid 19th-century organic chemistry developments involving researchers from institutions like the University of Paris and the Royal Society. Early ethnobotanical knowledge derived from Indigenous groups including the Huichol people, Navajo Nation, and communities in Mexico and Peru informed Western accounts documented by explorers and missionaries connected to expeditions under patrons such as the Royal Geographical Society. Chemists including those affiliated with the University of Freiburg and laboratories linked to the broader European scientific community contributed to structural elucidation during the late 1800s. In the 20th century, mescaline intersected with psychiatric research at clinics associated with the New York State Psychiatric Institute and experimental programs influenced by figures related to Timothy Leary and the American Psychiatric Association, while legal responses paralleled legislation like the Narcotic Drug Import and Export Act and later listings by the United Nations Commission on Narcotic Drugs.

Chemistry and pharmacology

Mescaline is a phenethylamine derivative chemically characterized alongside compounds studied at the Max Planck Society and within curricula at the Massachusetts Institute of Technology. Structural comparisons are routinely made with classic psychedelics investigated at the Sandoz Laboratories and universities such as Columbia University that explored indoleamines and phenethylamines. Pharmacologically, mescaline acts primarily as an agonist or partial agonist at serotonin receptors implicated in psychedelic effects, receptors also examined in research at institutions like the National Institutes of Health and the Karolinska Institute. The compound’s molecular profile situates it amid substances analyzed by analytical chemistry groups at facilities like the American Chemical Society and covered in textbooks used at the University of Oxford.

Effects and subjective experience

Users report perceptual alterations, mood changes, and cognitive shifts documented in case series and observational studies from hospitals and clinics affiliated with Beth Israel Deaconess Medical Center, UCLA Medical Center, and other medical centers. Comparisons are drawn to experiences reported for compounds that featured in studies at Imperial College London and historical narratives connected to the Beat Generation and artists associated with San Francisco cultural scenes. Phenomenology described in ethnographies from researchers at the Smithsonian Institution and fieldwork tied to the American Anthropological Association highlights ritualized contexts among groups such as the Huichol people and ceremonies noted in accounts tied to the Native American Church.

Pharmacokinetics and metabolism

Pharmacokinetic parameters have been measured in clinical pharmacology studies hosted by centers like Mayo Clinic and analyzed using methodologies refined at the European Medicines Agency and laboratories connected to the Food and Drug Administration. Mescaline is orally active with absorption, distribution, metabolism, and excretion profiles that have been compared with other phenethylamines in pharmacology reviews published by scholars affiliated with Johns Hopkins University School of Medicine and analytical groups at the University of California, San Francisco.

Medical and therapeutic research

Clinical and exploratory research has investigated mescaline’s potential in treating mood disorders and end-of-life distress in trials and case reports connected to institutions like Johns Hopkins University, New York University School of Medicine, and centers participating in the renaissance of psychedelic research funded by foundations such as the Beckley Foundation. Investigations into mechanism and therapeutic models reference translational neuroscience programs at places such as the National Institute of Mental Health and collaborative initiatives involving the Imperial College London psychedelics research unit.

Legal status and regulation

Regulatory frameworks for mescaline have been shaped by national agencies including the Drug Enforcement Administration, Health Canada, and the European Commission, with scheduling decisions influenced by treaties like the Single Convention on Narcotic Drugs and deliberations at the United Nations Office on Drugs and Crime. Domestic legal developments have intersected with Indigenous rights cases and precedents involving the Native American Church and rulings in courts such as the United States Supreme Court that addressed sacramental exemptions and religious freedom claims.

Risks, toxicity, and interactions

Safety profiles, adverse event reports, and toxicology data have been compiled by emergency departments at hospitals including Mount Sinai Hospital and reviewed in toxicology resources used by the American Association of Poison Control Centers. Risks described include psychological distress and physiological effects that may interact with medications metabolized by pathways studied at institutions such as the University of Cambridge and the Scripps Research Institute, including potential interactions with serotonergic agents regulated in formularies at academic medical centers like Massachusetts General Hospital.

Category:Psychedelics